NASDAQ:ZIOP - ZIOPHARM Oncology Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.39 -0.13 (-2.88 %) (As of 05/19/2019 11:09 AM ET)Previous Close$4.39Today's Range$4.39 - $4.5852-Week Range$1.56 - $5.00Volume886,686 shsAverage Volume1.27 million shsMarket Capitalization$712.45 millionP/E RatioN/ADividend YieldN/ABeta2.64 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells. Its lead gene therapy product candidate is Ad-RTS-hIL-12 plus veledimex, which is in Phase I clinical trial, to treat patients with recurrent glioblastoma and breast cancer. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; research and development agreement with the National Cancer Institute, and Ares Trading S.A. The company is headquartered in Boston, Massachusetts. Receive ZIOP News and Ratings via Email Sign-up to receive the latest news and ratings for ZIOP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ZIOP Previous Symbol CUSIP98973P10 CIK1107421 Webwww.ziopharm.com Phone617-259-1970Debt Debt-to-Equity Ratio0.01 Current Ratio8.89 Quick Ratio8.89Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$150,000.00 Price / Sales4,749.69 Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book9.54Profitability EPS (Most Recent Fiscal Year)($0.48) Net Income$-53,120,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-320.63%Miscellaneous Employees48 Outstanding Shares162,290,000Market Cap$712.45 million Next Earnings Date8/14/2019 (Estimated) OptionableOptionable ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions What is ZIOPHARM Oncology's stock symbol? ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP." How were ZIOPHARM Oncology's earnings last quarter? ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) issued its quarterly earnings data on Wednesday, May, 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.01. View ZIOPHARM Oncology's Earnings History. When is ZIOPHARM Oncology's next earnings date? ZIOPHARM Oncology is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for ZIOPHARM Oncology. What price target have analysts set for ZIOP? 5 brokers have issued twelve-month target prices for ZIOPHARM Oncology's stock. Their predictions range from $5.00 to $7.50. On average, they anticipate ZIOPHARM Oncology's stock price to reach $6.25 in the next year. This suggests a possible upside of 42.4% from the stock's current price. View Analyst Price Targets for ZIOPHARM Oncology. What is the consensus analysts' recommendation for ZIOPHARM Oncology? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last year. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ZIOPHARM Oncology. What are Wall Street analysts saying about ZIOPHARM Oncology stock? Here are some recent quotes from research analysts about ZIOPHARM Oncology stock: 1. According to Zacks Investment Research, "ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. " (5/18/2019) 2. HC Wainwright analysts commented, "We have updated our model to reflect the reported 1Q19 financial results, and we project revenues of $3.2M and a net loss of $0.33 per share for 2019. The company reported cash and cash equivalents of $51.5M at the end of 1Q19, which we believe is sufficient to maintain operations until 2Q20. Clinical updates on controlled IL-12 at ASCO. Management announced that two clinical updates on its controlled IL-12 program (Ad-RTS-hIL-12 plus veledimex) for the treatment of recurrent GBM (rGBM) are expected to be presented at the 2019 Oncology (ASCO) Annual Meeting in June. Recall, Ziopharm is conducting two Phase 1 studies to evaluate the IL-12 platform as a monotherapy or as combination therapy with nivolumab (marketed by Bristol-Myers Squibb (BMY; not rated) as Opdivo)." (5/9/2019) Has ZIOPHARM Oncology been receiving favorable news coverage? Headlines about ZIOP stock have been trending positive recently, InfoTrie reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ZIOPHARM Oncology earned a news impact score of 2.2 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. Who are some of ZIOPHARM Oncology's key competitors? Some companies that are related to ZIOPHARM Oncology include Amicus Therapeutics (FOLD), Biohaven Pharmaceutical (BHVN), Reata Pharmaceuticals (RETA), Arena Pharmaceuticals (ARNA), Mirati Therapeutics (MRTX), Intercept Pharmaceuticals (ICPT), Amneal Pharmaceuticals (AMRX), The Medicines (MDCO), Myokardia (MYOK), PTC Therapeutics (PTCT), Emergent Biosolutions (EBS), Insmed (INSM), Uniqure (QURE), Ligand Pharmaceuticals (LGND) and Portola Pharmaceuticals (PTLA). What other stocks do shareholders of ZIOPHARM Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Intrexon (XON), Celgene (CELG), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Synergy Pharmaceuticals (SGYP), Opko Health (OPK), Arena Pharmaceuticals (ARNA), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Amarin (AMRN). Who are ZIOPHARM Oncology's key executives? ZIOPHARM Oncology's management team includes the folowing people: Dr. Laurence James Neil Cooper, CEO & Director (Age 54)Dr. David M. Mauney M.D., Pres (Age 50)Mr. Kevin G. Lafond, Sr. VP of Fin., Chief Accounting Officer & Treasurer (Age 63)Ms. Lynn M. Ferrucci PHR, Sr. VP of HR, Facilities, IT & Admin.Mr. David Connolly, VP of Corp. Communications & Investor Relations Who are ZIOPHARM Oncology's major shareholders? ZIOPHARM Oncology's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.83%), Geode Capital Management LLC (1.08%), Northern Trust Corp (1.03%), Morgan Stanley (0.75%), Charles Schwab Investment Management Inc. (0.51%) and California State Teachers Retirement System (0.12%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney and Laurence James Neil Cooper. View Institutional Ownership Trends for ZIOPHARM Oncology. Which institutional investors are selling ZIOPHARM Oncology stock? ZIOP stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Ibex Investors LLC, Morgan Stanley, Private Advisor Group LLC, Virtu Financial LLC, The Manufacturers Life Insurance Company , Commonwealth Equity Services LLC and California State Teachers Retirement System. View Insider Buying and Selling for ZIOPHARM Oncology. Which institutional investors are buying ZIOPHARM Oncology stock? ZIOP stock was purchased by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, BlackRock Inc., Iridian Asset Management LLC CT, Charles Schwab Investment Management Inc., HighTower Advisors LLC, State of Wisconsin Investment Board, BNP Paribas Arbitrage SA and BlueCrest Capital Management Ltd. Company insiders that have bought ZIOPHARM Oncology stock in the last two years include David M Md Mauney and Laurence James Neil Cooper. View Insider Buying and Selling for ZIOPHARM Oncology. How do I buy shares of ZIOPHARM Oncology? Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is ZIOPHARM Oncology's stock price today? One share of ZIOP stock can currently be purchased for approximately $4.39. How big of a company is ZIOPHARM Oncology? ZIOPHARM Oncology has a market capitalization of $712.45 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-53,120,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. ZIOPHARM Oncology employs 48 workers across the globe. What is ZIOPHARM Oncology's official website? The official website for ZIOPHARM Oncology is http://www.ziopharm.com. How can I contact ZIOPHARM Oncology? ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected] MarketBeat Community Rating for ZIOPHARM Oncology (NASDAQ ZIOP)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 306 (Vote Outperform)Underperform Votes: 339 (Vote Underperform)Total Votes: 645MarketBeat's community ratings are surveys of what our community members think about ZIOPHARM Oncology and other stocks. Vote "Outperform" if you believe ZIOP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZIOP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: What is a Fibonacci Channel? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.